Thursday, November 21, 2019 5:45:54 AM
JL, I am not in the BO camp either. I wasn't hoping for a BO announcement, which would be unreasonable anyway, because given a hefty price tag, it would be a very risky endeavor until approval and generics settlement are out of the picture.
I was actually hoping for an EU partnership announcement with solid royalties and a nice upfront payment to pay for an even more aggressive salesforce growth.
To be honest, now that I am wrong, I need to sit down and think again. This Oppenheimer attack makes no sense. There must be an explanation. Either those guys are idiots and really bad at it or this attack was planned in a hurry, a total panic mode. Why?
You said it yourself, that the purpose of the attack is to lower the SP, so they could either cover or pick up more shares. Why the urgency and with such a radical approach? It would make way more sense to seed some doubt and recommend a price target like $15, which would be even lower than idiotic GS, but still could be possibly explained that the analyst just has some science comprehension problems. But no, not a single point in the entire Oppenheimer report makes any sense. Like it was literally crafted by a person who was given a task to organize an attack and they only had an hour to skim through all the papers. I think the only viable explanation I have so far is ACST offering tomorrow led by Oppenheimer (again).
Kim
I was actually hoping for an EU partnership announcement with solid royalties and a nice upfront payment to pay for an even more aggressive salesforce growth.
To be honest, now that I am wrong, I need to sit down and think again. This Oppenheimer attack makes no sense. There must be an explanation. Either those guys are idiots and really bad at it or this attack was planned in a hurry, a total panic mode. Why?
You said it yourself, that the purpose of the attack is to lower the SP, so they could either cover or pick up more shares. Why the urgency and with such a radical approach? It would make way more sense to seed some doubt and recommend a price target like $15, which would be even lower than idiotic GS, but still could be possibly explained that the analyst just has some science comprehension problems. But no, not a single point in the entire Oppenheimer report makes any sense. Like it was literally crafted by a person who was given a task to organize an attack and they only had an hour to skim through all the papers. I think the only viable explanation I have so far is ACST offering tomorrow led by Oppenheimer (again).
Kim
Recent AMRN News
- Amarin Highlights New REDUCE-IT Analysis Showing Risk-Weighted ApoB May Improve Cardiovascular Risk Detection (AMRN) • IH Market News • 05/27/2026 03:24:38 PM
- New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia • GlobeNewswire Inc. • 05/27/2026 12:00:00 PM
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
